164 related articles for article (PubMed ID: 32329406)
1. Evaluation of two functional CD24 polymorphisms in primary sclerosing cholangitis.
Zhang CC; Voitl R; Hippchen T; Weiss KH; Sauer P; Rupp C
Scand J Gastroenterol; 2020 May; 55(5):581-587. PubMed ID: 32329406
[No Abstract] [Full Text] [Related]
2. Genetic polymorphisms associated with inflammatory bowel disease do not confer risk for primary sclerosing cholangitis.
Karlsen TH; Hampe J; Wiencke K; Schrumpf E; Thorsby E; Lie BA; Broomé U; Schreiber S; Boberg KM
Am J Gastroenterol; 2007 Jan; 102(1):115-21. PubMed ID: 17100974
[TBL] [Abstract][Full Text] [Related]
3. Role of CD24 polymorphisms in the susceptibility to inflammatory bowel disease.
Lisiansky V; Kraus S; Naumov I; Kazanov D; Nabiochtchikov I; Toledano O; Leshno M; Avivi D; Dotan I; Arber N; Moshkowitz M
Int J Biol Markers; 2014 Mar; 29(1):e62-8. PubMed ID: 24557789
[TBL] [Abstract][Full Text] [Related]
4. Fut2 genotype is a risk factor for dominant stenosis and biliary candida infections in primary sclerosing cholangitis.
Rupp C; Friedrich K; Folseraas T; Wannhoff A; Bode KA; Weiss KH; Schirmacher P; Sauer P; Stremmel W; Gotthardt DN
Aliment Pharmacol Ther; 2014 Apr; 39(8):873-82. PubMed ID: 24612312
[TBL] [Abstract][Full Text] [Related]
5. CD24 single nucleotide polymorphisms and cancer risk.
Yan S; Xu D; Jiang T; Wang P; Yin Y; Wang X; Hua C; Zhang B; Li Z; Lu L; Liu X; Wang B; Zhang D; Zhang R; Sun B; Wang X
Tumour Biol; 2014 Sep; 35(9):8927-32. PubMed ID: 24894672
[TBL] [Abstract][Full Text] [Related]
6. MMP-2 is a disease-modifying gene in primary sclerosing cholangitis.
Korkmaz KS; de Rooij BJ; van Hoek B; Janse M; Coenraad MJ; van der Reijden JJ; Weersma RK; Porte RJ; Voorneveld PW; Baranski AG; Verspaget HW
Liver Int; 2014 Feb; 34(2):274-80. PubMed ID: 23809662
[TBL] [Abstract][Full Text] [Related]
7. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9.
Janse M; Lamberts LE; Franke L; Raychaudhuri S; Ellinghaus E; Muri Boberg K; Melum E; Folseraas T; Schrumpf E; Bergquist A; Björnsson E; Fu J; Jan Westra H; Groen HJ; Fehrmann RS; Smolonska J; van den Berg LH; Ophoff RA; Porte RJ; Weismüller TJ; Wedemeyer J; Schramm C; Sterneck M; Günther R; Braun F; Vermeire S; Henckaerts L; Wijmenga C; Ponsioen CY; Schreiber S; Karlsen TH; Franke A; Weersma RK
Hepatology; 2011 Jun; 53(6):1977-85. PubMed ID: 21425313
[TBL] [Abstract][Full Text] [Related]
8. Association of the tumour necrosis factor alpha -308 but not the interleukin 10 -627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis.
Mitchell SA; Grove J; Spurkland A; Boberg KM; Fleming KA; Day CP; Schrumpf E; Chapman RW;
Gut; 2001 Aug; 49(2):288-94. PubMed ID: 11454808
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the influence of two CD24 genetic variants in Crohn's disease and ulcerative colitis.
Diaz-Gallo LM; Medrano LM; Gómez-García M; Cardeña C; Rodrigo L; Mendoza JL; Taxonera C; Nieto A; Alcain G; Cueto I; López-Nevot MA; Urcelay E; Martin J
Hum Immunol; 2011 Oct; 72(10):969-72. PubMed ID: 21684315
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms of matrix metalloproteinase 3 in primary sclerosing cholangitis.
Juran BD; Atkinson EJ; Schlicht EM; Larson JJ; Ellinghaus D; Franke A; Lazaridis KN
Liver Int; 2011 Jul; 31(6):785-91. PubMed ID: 21134112
[TBL] [Abstract][Full Text] [Related]
11. Association of CD24 gene polymorphisms with susceptibility to biopsy-proven giant cell arteritis.
Rueda B; Miranda-Filloy JA; Martin J; Gonzalez-Gay MA
J Rheumatol; 2008 May; 35(5):850-4. PubMed ID: 18381780
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features.
Palmela C; Peerani F; Castaneda D; Torres J; Itzkowitz SH
Gut Liver; 2018 Jan; 12(1):17-29. PubMed ID: 28376583
[TBL] [Abstract][Full Text] [Related]
13. Analysis of MAdCAM-1 and ICAM-1 polymorphisms in 365 Scandinavian patients with primary sclerosing cholangitis.
Bowlus CL; Karlsen TH; Broomé U; Thorsby E; Vatn M; Schrumpf E; Lie BA; Boberg KM
J Hepatol; 2006 Nov; 45(5):704-10. PubMed ID: 16750586
[TBL] [Abstract][Full Text] [Related]
14. Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease.
Naess S; Björnsson E; Anmarkrud JA; Al Mamari S; Juran BD; Lazaridis KN; Chapman R; Bergquist A; Melum E; Marsh SG; Schrumpf E; Lie BA; Boberg KM; Karlsen TH; Hov JR
Liver Int; 2014 Nov; 34(10):1488-95. PubMed ID: 24517468
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility to primary sclerosing cholangitis is associated with polymorphisms of intercellular adhesion molecule-1.
Yang X; Cullen SN; Li JH; Chapman RW; Jewell DP
J Hepatol; 2004 Mar; 40(3):375-9. PubMed ID: 15123348
[TBL] [Abstract][Full Text] [Related]
16. Cystic fibrosis transmembrane conductance regulator gene polymorphisms in patients with primary sclerosing cholangitis.
Henckaerts L; Jaspers M; Van Steenbergen W; Vliegen L; Fevery J; Nuytten H; Roskams T; Rutgeerts P; Cassiman JJ; Vermeire S; Cuppens H
J Hepatol; 2009 Jan; 50(1):150-7. PubMed ID: 18992954
[TBL] [Abstract][Full Text] [Related]
17. Analysis of IL2/IL21 gene variants in cholestatic liver diseases reveals an association with primary sclerosing cholangitis.
Stallhofer J; Denk GU; Glas J; Laubender RP; Göke B; Rust C; Brand S; Pusl T
Digestion; 2011; 84(1):29-35. PubMed ID: 21304239
[TBL] [Abstract][Full Text] [Related]
18. Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis.
Alberts R; de Vries EMG; Goode EC; Jiang X; Sampaziotis F; Rombouts K; Böttcher K; Folseraas T; Weismüller TJ; Mason AL; Wang W; Alexander G; Alvaro D; Bergquist A; Björkström NK; Beuers U; Björnsson E; Boberg KM; Bowlus CL; Bragazzi MC; Carbone M; Chazouillères O; Cheung A; Dalekos G; Eaton J; Eksteen B; Ellinghaus D; Färkkilä M; Festen EAM; Floreani A; Franceschet I; Gotthardt DN; Hirschfield GM; Hoek BV; Holm K; Hohenester S; Hov JR; Imhann F; Invernizzi P; Juran BD; Lenzen H; Lieb W; Liu JZ; Marschall HU; Marzioni M; Melum E; Milkiewicz P; Müller T; Pares A; Rupp C; Rust C; Sandford RN; Schramm C; Schreiber S; Schrumpf E; Silverberg MS; Srivastava B; Sterneck M; Teufel A; Vallier L; Verheij J; Vila AV; Vries B; Zachou K; ; Chapman RW; Manns MP; Pinzani M; Rushbrook SM; Lazaridis KN; Franke A; Anderson CA; Karlsen TH; Ponsioen CY; Weersma RK
Gut; 2018 Aug; 67(8):1517-1524. PubMed ID: 28779025
[TBL] [Abstract][Full Text] [Related]
19. Advances and controversies in the pathogenesis and management of primary sclerosing cholangitis.
Eksteen B
Br Med Bull; 2014 Jun; 110(1):89-98. PubMed ID: 24795363
[TBL] [Abstract][Full Text] [Related]
20. PSC associated inflammatory bowel disease: a distinct entity.
Beheshti-Maal A; Tamimi A; Iravani S; Memarnejadian A; Sorouri M; Aghdaei HA; Zali MR; Hossein Khannazer N; Vosough M
Expert Rev Gastroenterol Hepatol; 2022 Feb; 16(2):129-139. PubMed ID: 35078376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
